Literature DB >> 7272506

Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant disease.

J D Rowley, H M Golomb, J W Vardiman.   

Abstract

Cytogenetic studies were performed on 26 patients who developed acute nonlymphocytic leukemia (ANLL) or a dysmyelopoietic syndrome after treatment of a primary malignancy. Fifteen patients had radiotherapy and chemotherapy, seven had only chemotherapy, and four had only radiotherapy. The median times from diagnosis of the initial disease to the development of bone marrow dysfunction for these treatment groups were 50, 46, and 49 mo, respectively. Twenty-five patients had an abnormal karyotype in myeloid cells. Loss of part or all of no. 5 and/or no. 7 was noted in 23 of 25 patients with aneuploidy. Loss of no. 5 was noted only in patients who previously had malignant lymphoma, whereas loss of no. 7 was seen in these patients as well as in those who had other malignancies. Abnormalities of both nos. 5 and 7 occurred in 53% of the patients treated with combined therapy and in only 27% of patients treated with either modality alone. Although these changes are distinctly different from those noted in lymphomas, they are similar to those seen in 25% of aneuploid patients with ANLL de novo.

Entities:  

Mesh:

Year:  1981        PMID: 7272506

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  49 in total

Review 1.  Current understanding of the mechanism of benzene-induced leukemia in humans: implications for risk assessment.

Authors:  Cliona M McHale; Luoping Zhang; Martyn T Smith
Journal:  Carcinogenesis       Date:  2011-12-12       Impact factor: 4.944

Review 2.  Haematology.

Authors:  N T O'Connor
Journal:  Postgrad Med J       Date:  1990-08       Impact factor: 2.401

Review 3.  Therapy-related myeloid neoplasms: pathobiology and clinical characteristics.

Authors:  H Sill; W Olipitz; A Zebisch; E Schulz; A Wölfler
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

4.  Long-term risk for subsequent leukemia after treatment for childhood cancer: a report from the Childhood Cancer Survivor Study.

Authors:  Kerri Nottage; Jennifer Lanctot; Zhenghong Li; Joseph P Neglia; Smita Bhatia; Sue Hammond; Wendy Leisenring; Anna Meadows; Deokumar Srivastava; Leslie L Robison; Gregory T Armstrong
Journal:  Blood       Date:  2011-04-15       Impact factor: 22.113

5.  Acute leukemia in a patient cured of diffuse histiocytic lymphoma.

Authors:  J P Dutcher; P H Wiernik
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

6.  Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility.

Authors:  Jeffrey A Knight; Andrew D Skol; Abhijit Shinde; Darcie Hastings; Richard A Walgren; Jin Shao; Thelma R Tennant; Mekhala Banerjee; James M Allan; Michelle M Le Beau; Richard A Larson; Timothy A Graubert; Nancy J Cox; Kenan Onel
Journal:  Blood       Date:  2009-03-18       Impact factor: 22.113

Review 7.  Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia.

Authors:  Zhijian Qian; John M Joslin; Thelma R Tennant; Shalini C Reshmi; David J Young; Angela Stoddart; Richard A Larson; Michelle M Le Beau
Journal:  Chem Biol Interact       Date:  2009-12-01       Impact factor: 5.192

8.  Detection of numerical chromosomal abnormalities in neoplastic hematopoietic cells by in situ hybridization with a chromosome-specific probe.

Authors:  J Anastasi; M M Le Beau; J W Vardiman; C A Westbrook
Journal:  Am J Pathol       Date:  1990-01       Impact factor: 4.307

9.  Second cancers in patients with the Ewing sarcoma family of tumours.

Authors:  Fariba Navid; Catherine Billups; Tiebin Liu; Matthew J Krasin; Carlos Rodriguez-Galindo
Journal:  Eur J Cancer       Date:  2008-03-18       Impact factor: 9.162

10.  Multicenter validation study of a transplantation-specific cytogenetics grouping scheme for patients with myelodysplastic syndromes.

Authors:  P Armand; H J Deeg; H T Kim; H Lee; P Armistead; M de Lima; V Gupta; R J Soiffer
Journal:  Bone Marrow Transplant       Date:  2009-09-28       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.